Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost‐effectiveness analysis
Adding sintilimab to chemoradiotherapeutic regimens represents an innovative and cost-effective means for patients with locoregionally advanced NPC management in China.
Authors
- Youwen Zhu (ORCID: https://orcid.org/0000-0001-8692-3591)
- Hong Zhu (ORCID: https://orcid.org/0009-0000-8919-6203)
- Shan Li (ORCID: https://orcid.org/0000-0002-8457-3994)
- Kun Liu (ORCID: https://orcid.org/0000-0001-6720-3310)
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Head & Neck
- Published
- 2024-09-08
- DOI
- https://doi.org/10.1002/hed.27932
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Natural Science Foundation of China
- Xiangya Hospital, Central South University